Skip to content

Innovative, accessible treatments for the leading causes of death globally

At George Medicines, we believe affordable, single-pill combinations of existing medicines offer the potential to better manage non-communicable diseases and could have a huge positive social impact by improving lives and reducing the financial burden on patients and health systems.

About Us +

Welcome to
George Medicines

Multiple drugs are increasingly being prescribed to adequately control conditions such as hypertension, cardiovascular disease and type 2 diabetes. This can be complicated for patients and costly for health systems. At George Medicines we are using our drug development expertise and the latest formulation approaches to combine existing medicines into novel single-pill therapies with the potential to bring significant improvements in clinical outcomes and adherence.

Our Approach +

About Us

George Medicines is a late-stage drug development company focused on improving the management of non-communicable diseases with innovative, affordable, single-pill combinations of existing medicines. Combining best-in-class molecules from existing medicines in fixed- and low-dose formulations, George Medicines is developing innovative and proprietary treatments with the potential to be more efficacious, safer and more affordable than currently available treatment options.

MORE INFO +

Our Approach

George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases. Our disruptive and transformative business model avoids the early, high-risk stages of drug discovery and development by formulating established drugs into innovative, single-pill combinations using proprietary technology, which reduces time-to-market and brings a higher probability of success while requiring less capital investment than is usual in the industry.

MORE INFO +

Pipeline

We are building a strong and diversified proprietary pipeline of innovative, affordable, single-pill combination therapies in late-stage development, targeting some of the biggest killers in both developed and developing countries, include cardiovascular disease, hypertension, and type 2 diabetes.

MORE INFO +

Partners

Our strategy is to advance our late-stage pipeline through the final stages of development and to secure approval from global regulators. We work alongside appropriate partners to commercialise our therapies across the developed and developing world where our medicines can reduce the burden on health systems and have the biggest positive social impact

MORE INFO +

Latest News

01/07/21

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension

Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research. Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such as CVD and Diabetes. London, UK, 1 July 2021 …

READ MORE+
03/06/21

George Medicines appoints Stefan König as Chief Executive Officer

Mr König joins to lead late-stage drug development company developing proprietary fixed dose combination therapies for non-communicable diseases. US FDA grants IND authorization to commence Phase III trials with triple combination candidate for the treatment of hypertension. Chief Business Officer, Karl Roberts, appointed to new role of Chief Operating Officer. London, UK, 3 June 2021 – …

READ MORE+

Chairman’s Statement

“George Medicines is uniquely positioned to change the lives of the more than 2 billion people around the world suffering from non-communicable diseases with our novel single-pill therapies. By targeting underserved populations in established and emerging markets, we are making better medicines for all. And never was it more urgent, as the pandemic has highlighted weaknesses and inequalities in health systems globally”

Professor Stephen MacMahon AO, Chairman, Board of George Medicines

Part of a mission to deliver affordable and scalable treatments and technologies

George Medicines is one of George Health’s four businesses, created to commercialise medicines and technologies that leverage the George Institute’s late-stage clinical research for chronic disease.

VIEW WEBSITE +

George
Health


Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities

George
Clinical


Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities

George Health Technology


Affordable, personalised digital health care for all.

Ellen Medical Devices


The world’s first affordable dialysis system